Observational studyFuture oncology (London, England)2025

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.

Nicholas Robert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.